ATRA has wide applications in acute promyelocytic leukaemia (APL) patients; it targets PML/RARα infusion protein, provokes terminal differentiation of promyelocytes [21, 22], and transforms APL from a highly fatal disease to highly curable disease [20]. The gene discussed is PML; the disease is acute promyelocytic leukemia.